Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant
Open Access
- 3 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 155, 105253
Abstract
No abstract availableKeywords
Funding Information
- Korea Disease Control and Prevention Agency (6300-6331-301)
This publication has 12 references indexed in Scilit:
- The significant immune escape of pseudotyped SARS-CoV-2 variant OmicronEmerging Microbes & Infections, 2021
- Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021Eurosurveillance, 2021
- SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infectionmedRxiv, 2021
- Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y MA30 strain of SARS-CoV-2bioRxiv, 2021
- Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or VaccinationClinical Infectious Diseases, 2021
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- SARS-CoV-2 variants, spike mutations and immune escapeNature Reviews Microbiology, 2021
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraCell, 2021
- SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodiesmedRxiv, 2021
- Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variantsEmerging Microbes & Infections, 2021